Startupticker.ch

The European Patent Office (EPO) has carried out a study to identify the universities from which start-ups use research results. Three Swiss universities made it to the Top 12. It is therefore not surprising that Swiss start-ups also stand out in Europe when it comes to the number of patents, confirming that Switzerland is the place to be for deep tech start-ups. ETH Zürich EPFL University of Zurich #deeptech #patents #knowledgetransfer https://lnkd.in/eyv3Mm9S

Receiving the De Novo approval by the U.S. Food and Drug Administration (FDA) allows Distalmotion to market the Dexter Surgical Robot for adult inguinal hernia repair. 90% of inguinal hernia repairs in the United States are currently performed in the hospital outpatient and ambulatory surgery centers.  Dexter’s mobile design, combined with its small form factor, make it particularly well-suited to these environments, allowing hospitals and ambulatory surgery centers (ASCs) to optimize resources while still accessing the latest technologies and best-in-class surgical tools. With more than 1,300 patients successfully treated in Europe, Distalmotion’s extensive experience has paved the way for bringing this innovation to the U.S. market. Greg Roche Michael Friedrich Distalmotion #surgicalrobot #FDAclearance https://lnkd.in/evumjm2d

For once, Switzerland comes off badly in a ranking: according to the 'Not Optional' campaign led by Venture Index, Switzerland has a stock option policy that is particularly disadvantageous for start-ups. Switzerland is in 25th and last place with fewer points than any other country in the comparison. https://lnkd.in/gM3Qeh7E According to the initiative, “Switzerland is one of the few ‘ripe for change’ countries that have made no meaningful progress in stock option reform since the launch of the Not Optional campaign.” In contrast, three largest economies – Germany, France, and the UK – have reformed stock option policies so they match or exceed the US. Simon Enderli Swiss Entrepreneurs & Startup Association SWESA Raphael Tobler Swiss Startup Association Karim Maizar #stockoptions

Three Geneva-based startups, spanning Cleantech, Life Sciences, and Virtual Reality, have been awarded financing through the FONGIT Innovation Fund (FIF). The selected companies, Dyneo Technologies, Adoram Therapeutics, and ex vivo, have received a combined total of 250,000 CHF in FIF funding, including Seed Loans and Grants, to advance their groundbreaking technologies and solutions. Max Carrel Dyneo Technologies SA David Pejoski Adoram Therapeutics Oliver A Kannape FONGIT https://lnkd.in/ecaJAEyf

Über 10'000 Kunden aus dem DACH-Raum haben beim Zuger Startup adretto Anzüge und Smokings für spezielle Anlässe gemietet. Doch nun ist Schluss und adretto musste Insolvenz anmelden. Ein Gespräch mit Gründer und CEO Lorenz Pöhlmann zu den Hintergründen und einem ersten Fazit. Lorenz Pöhlmann #B2C #Setback https://lnkd.in/esDS8BR2

Nach einem etwas harten Start während der Pandemie, hat das Zürcher Startup Sundays Beverage seine «Hard Seltzer»-Getränke mittlerweile bei über 60 Retailern in die Regale gebracht. Für dieses Jahr rechnen die drei Gründerinnen mit dem Erreichen des Break-Even. Um die nächsten Skalierungsschritte zu unterstützen, sucht das Getränke-Startup derzeit über die Plattform Oomnium nach Aktionärinnen und Aktionären. Mehr als 400'000 Franken wurden bereits zugesagt. Die Kampagne läuft noch einige Tage. Mit dem frischen Kapital will das frauengeführte Startup das Sales-Team ausbauen, mehr Schub ins Marketing bringen und weitere Märkte für die Expansion sondieren. Bereits 2025 soll der Ausstoss auf 300'000 Einheiten verdreifacht werden. Katy Lee Norell Narum Jennifer Kedinger Sundays Beverage AG OOMNIUM AG #beverage #hardseltzer #crowdfunding https://lnkd.in/eixfXNdE

VCs are professional optimists. This was clearly evident at yesterday's VCs on stage event hosted by Seca. The investors in attendance had only one thing to think about – the lack of exits. Otherwise, even in the current situation, they saw several reasons to be optimistic The Swiss VC scene has grown up. Several VCs that were founded 15 or more years ago were able to present convincing figures on their returns in their pitches. The mature VCs with their impressive track records are also attracting more interest from pension funds. In addition, the decision-makers in pension funds increasingly come from a new generation. The outstanding technological performance of Swiss start-ups was also undisputed. There are plenty of promising investment cases. Historically, the VC funds that start up in crisis years are the ones with the highest returns. With this argument, numerous Swiss VCs are currently looking for investors. The Swiss VC funds are proving resilient in the current challenging times. So far, none of them have had to close their doors. Thanks to SECA - Swiss Private Equity & Corporate Finance Association for organising the event and to the VCs for sharing insights about their funds. Thomas Heimann, MSc Bernd Pfister Ulrich Geilinger Andrea Villiger

MobiLysis has just secured the University of Massachusetts Amherst (UMass) as its first customer in the USA. Presented a few days ago at the AI-X Summit in Zurich, the startup headed by Manos Barmpounakis has just flown its drones in 5 different large cities (Boston, Madrid, Athens, Geneva, Helsinki) in the last month and is generating a lot of interest. The company is on a mission to identify sources of congestion and mobility problems in cities. Manos Barmpounakis MobiLysis #trafficmanagement EPFL Startup https://lnkd.in/ecwgeSE7

ATANIS Biotech AG, a Bern-based company specializing in functional allergy diagnosis, completed an oversubscribed capital raise. The funds will be used to accelerate marketing efforts of FAST-PASE, a safe, functional ex vivo allergy assay. Jean-Pierre Kinet ATANIS Biotech AG Spectrum Value Management Ltd. #allergy #diagnostics https://lnkd.in/g6Treg6q

Die Basler Kantonalbank nutzt als erste Kundin die Lösung von MachinaLabs für vollautomatisch generierte Finanznachrichten. Weitere Plattform-Anwendungen werden in Pilotprojekten getestet. Nun ermöglicht die vor 2 Wochen angekündigte Teilnahme am Inkubator «100 fürs Baselbiet» und der grosszügige Kreditrahmen der BLKB mehr Schub für die nächsten Skalierungsschritte. Christian Dreyer Thierry Gilgen Renato Barba Andreas Ruesch MachinaLabs BLKB #genai #fintech https://lnkd.in/dZhmSFwc